Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 713

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 713
---
 | F-82  |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022                                                             |     | F-83  |
| Notes to the Consolidated Financial Statements                                                                                                   |     | F-84  |
| Condensed Consolidated Interim Balance Sheet (Unaudited) as of September 30, 2024 and December 31, 2023                                          |     | F-119 |
| Condensed Consolidated Interim Statements of Operations (Unaudited) for the three and nine months ended September 30, 2024 and 2023              |     | F-120 |
| Condensed Consolidated Interim Statements of Stockholders’ Equity (Deficiency) (Unaudited) for the nine months ended September 30, 2024 and 2023 |     | F-121 |
| Condensed Consolidated Interim Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2024 and 2023                        |     | F-122 |
| Notes to Condensed Consolidated Financial Statements (Unaudited)                                                                                 |     | F-123 |

### REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and Board of Directors of

#### Kintara Therapeutics, Inc.

### Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Kintara Therapeutics, Inc. (the “Company”) as of June 30, 2024 and 2023, the related consolidated statements of operations, stockholders’ equity and cash flows for each of the two years in the period ended June 30, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended June 30, 2024, in conformity with accounting principles generally accepted in the United States of America.

Explanatory Paragraph – Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1, the Company, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company’s